Hofseth BioCare ASA (LON:0Q6H)
London · Delayed Price · Currency is GBP · Price in NOK | Market Cap | 53.72M +3.2% |
| Revenue (ttm) | 19.05M -10.6% |
| Net Income | -10.76M |
| EPS | -0.03 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 222 |
| Open | 1.395 |
| Previous Close | n/a |
| Day's Range | 1.395 - 1.395 |
| 52-Week Range | 1.275 - 1.925 |
| Beta | 0.41 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 21, 2026 |
About Hofseth BioCare ASA
Hofseth BioCare ASA produces and sells health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, Turkey, rest of Europe, Japan, Asia, and the United States. The company offers ProGo, a bioactive peptide for weight management and metabolic health; OmeGo, a fish oil that provides a full spectrum of fatty acids and omegas; CalGo and NT-II, which are calcium collagen complexes that support joint and bone health; CollaGo; and PetGo, a non-soluble protein. Hofseth BioCare ASA was founded in 2000 a... [Read more]
Financial Performance
In 2025, Hofseth BioCare ASA's revenue was 256.34 million, a decrease of -3.46% compared to the previous year's 265.54 million. Losses were -134.88 million, 7.65% more than in 2024.
Financial numbers in NOK Financial StatementsNews
Hofseth BioCare ASA Quarterly report: Q1 2026
Hofseth BioCare ASA has published its Q1 2026 quarterly earnings report on June 30, 2026.
Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2026
The Annual General Meeting of Hofseth BioCare ASA for 2026 will be held at the company's premises at Keiser Wilhelms gate 24, 6003 Ålesund, on 30 June 2026 at 11:00 CEST.
Hofseth BioCare ASA: EXCLUSIVE LICENSE AND SUPPLY AGREEMENT SIGNED FOR PROGO FOR OVER $5M
Hofseth BioCare ASA (“HBC”) has entered into an Exclusive License and Supply Agreement (the “Agreement”) with Fission Holdings LLC (“Fission”), a US-based affiliate and sales channel operator headquar...
Hofseth BioCare ASA: HBC publishes paradigm-changing clinical trial results of OmeGo full spectrum omegas
HBC announces the publication of its head-to-head clinical trial results with its patented, full spectrum omegas brand, OmeGo®. The trial showed that OmeGo® increased the Omega 3 Index (O3I) by over 7...
Hofseth BioCare ASA: HBC ANNUAL REPORT 2025
The Board of Directors of Hofseth BioCare ASA ("HBC") has approved the financial statements for 2025, and HBC has today published the Annual Report and Sustainability Report for 2025. In October 2025,...
Hofseth BioCare ASA: FOURTH QUARTER 2025 FINANCIAL REPORT
HBC recorded total operating revenues of NOK 72.2 million in the fourth quarter of 2025, compared to NOK 64.9 million in the same period last year. Net operating revenues were NOK 71.1 million, up fro...
Hofseth BioCare ASA Annual report: Q4 2025
Hofseth BioCare ASA has published its Q4 2025 annual report on February 13, 2026.
Hofseth BioCare ASA Quarterly report: Q4 2025
Hofseth BioCare ASA has published its Q4 2025 quarterly earnings report on February 13, 2026.
Hofseth BioCare ASA: PRIMARY INSIDER NOTIFICATION
Christoph Baldegger, primary insider and member of the Board of Directors in Hofseth BioCare ASA ("HBC"), has subscribed for 368,320 Offer shares in the Subsequent Offering and Mr. Baldegger will hold...
Hofseth BioCare ASA: RESULTS OF SUBSEQUENT OFFERING
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR ...
Hofseth BioCare ASA: Extraordinary General Meeting completed
Hofseth BioCare ASA held an Extraordinary General Meeting on 20 November 2025. All proposals were resolved as presented in the notice issued on 30 October 2025.
Hofseth BioCare ASA: LAST DAY OF SUBSCRIPTION PERIOD IN SUBSEQUENT OFFERING
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR ...
Hofseth BioCare ASA: HBC ANNOUNCES STRATEGIC PRODUCT PARTNERSHIP WITH JAMES LAVALLE & METABOLIC ELITE
Hofseth BioCare (HBC), a global leader in sustainable marine-based nutrition, today announced a strategic product partnership with Metabolic Elite, with formulations being guided by key opinion leader...
Hofseth BioCare ASA: Publication of the Prospectus – Start of the Subscription Period for the Subsequent Offering
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR ...
Hofseth BioCare ASA: Terms of the Subsequent Offering
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR ...
Hofseth BioCare ASA Quarterly report: Q3 2025
Hofseth BioCare ASA has published its Q3 2025 quarterly earnings report on November 7, 2025.
Hofseth BioCare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING
Reference is made to the stock exchange announcement by Hofseth BioCare ASA ("HBC" or the "Company") on 27 October 2025 regarding (i) the completion of a private placement (the "Private Placement") of...
Hofseth BioCare ASA: Mandatory Notification of Trade
Reference is made to the stock exchange announcement by Hofseth Biocare ASA ("HBC" or the "Company") on 27 October 2025 regarding completion of a private placement (the "Private Placement") of new sha...
Ex. Subsequent Offering Today
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR ...
Hofseth BioCare ASA: Key Information Relating to Subsequent Offering
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR ...
Hofseth BioCare ASA: Disclosures of Large Shareholdings
Reference is made to the stock exchange announcement by Hofseth BioCare ASA ("HBC" or the "Company") on 27 October 2025 regarding completion of a private placement (the "Private Placement") of new sha...
Hofseth BioCare ASA: Private placement successfully placed
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR ...
Hofseth Biocare ASA: USD 5 Million Divestment in Aecorbio
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR ...
Hofseth BioCare ASA: Contemplated Private Placement and Partial Divestment of Shares in Aecorbio
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR ...
Hofseth Biocare ASA: AECORBIO SECURES A FURTHER $1.5M AT A $30M VALUATION FOR ONGOING FT-002A PEPTIDE DEVELOPMENT IN PROSTATE CANCER
AecorBio Inc., formerly known as HBC Immunology Inc, has successfully completed a further equity financing round of $1.5m from existing and new investors at a company valuation of $30 million. This fu...